Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
NCT06397677 · View on ClinicalTrials.gov ↗
Study Summary
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Conditions Studied
Interventions
- GENETIC Research Testing Performed (Laboratory)
- DIAGNOSTIC_TEST Information Collected as Standard of Care
- OTHER Research Testing Performed
Study Locations (4)
California
- University of California San Francisco — San Francisco
Colorado
- University of Colorado Denver — Aurora
Kansas
- University of Kansas — Kansas City
Michigan
- University of Michigan — Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2034-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06397677
The ClinicalTrials.gov registry entry for NCT06397677 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,447 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions — of which Research Testing Performed (Laboratory) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06397677 reports 4 study locations spanning 4 distinct geographic areas — top geographies include California, Colorado, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06397677 about?
NCT06397677 is a clinical study titled "Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease". A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progressi...
What is the current status of trial NCT06397677?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2024-01-22. Estimated completion is 2034-01.
What conditions does trial NCT06397677 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Interstitial Lung Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06397677?
The interventions under investigation include: Research Testing Performed (Laboratory) (GENETIC), Information Collected as Standard of Care (DIAGNOSTIC_TEST), Research Testing Performed (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06397677?
This trial is sponsored by University of Colorado, Denver, which has 1,447 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06397677 being conducted?
This trial has 4 study locations across California, Colorado, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.